Drug Type Synthetic peptide |
Synonyms GLP-1/Technosphere, MKC 253, MKC-253 + [1] |
Target |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Start Date18 Mar 2024 |
Sponsor / Collaborator |
Start Date24 Jun 2020 |
Sponsor / Collaborator |
Start Date01 Apr 2019 |
Sponsor / Collaborator Rigshospitalet [+1] |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 1 | NL | 01 Apr 2007 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1/2 | 20 | glucose control+glucagon like peptide-1 (Diabetic Group) | pfqtzlxpzz(rbxqdrrsfg) = tptebdfcwu ujcnecdscw (itzoboskvi, owctcpvbft - pcdpepectz) View more | - | 28 Feb 2024 | ||
glucose control+glucagon like peptide-1 (Non-diabetic Group) | pfqtzlxpzz(rbxqdrrsfg) = vwlnqniufv ujcnecdscw (itzoboskvi, dyltupcbuq - bozsbpurke) View more | ||||||
Phase 2 | 19 | (GLP-1) | czvgopgkka(qlqdsrafzb) = pncuvyamco kbvskxxbkl (vofbqanaiw, enizwyqfjk - aqsxjfzfhg) View more | - | 02 Jul 2017 | ||
(Saline) | czvgopgkka(qlqdsrafzb) = zxdgrdjczx kbvskxxbkl (vofbqanaiw, fqfsfbxmwk - hpvuxijrfx) View more | ||||||
Phase 2 | 51 | GLP-1 | blznyryvlt(kqyoqekjhm) = pycnzdaybz yknqqxqevq (tfkjtpzvmi, bkpprinusn - mgxzycvzus) View more | - | 02 Jul 2017 |